Fundación Gecp

This phase 3 trial tests whether two immunotherapy drugs, sacituzumab and zimberelimab, can keep lung cancer from returning after surgery. It includes 129 patients whose cancer did not fully disappear with pre-surgery treatment. Participants are split into three groups: observati…

This study tests a drug called tarlatamab as a maintenance treatment for people with limited-stage small cell lung cancer who cannot receive standard combined chemotherapy and radiation. After completing chemotherapy with or without radiation, participants who have not gotten wor…

This phase 2 trial is testing a daily pill called sotorasib (AMG510) in people with stage III lung cancer that has a specific genetic change (KRAS G12C) and cannot be treated with standard chemotherapy plus radiation. The study will enroll about 19 participants to see if the drug…

This study tests whether a simple blood test (ctDNA) can help doctors decide if adding chemotherapy to the immunotherapy drug cemiplimab works better for advanced lung cancer. About 63 people with stage IV or stage IIIB/C non-small cell lung cancer that hasn't been treated before…

This study tests a drug called atezolizumab (Tecentriq) plus standard chemotherapy in 97 people with stage III non-small cell lung cancer. After initial treatment, some may have surgery, while others continue on atezolizumab. The goal is to see if this approach helps keep the can…

This study reviews medical records from 150 people with stage IIIA lung cancer who had chemotherapy before surgery. Researchers want to see if the amount of tumor killed by the treatment predicts how long patients live without cancer coming back. No new treatments are tested; the…

This observational study follows 50 people with stage III non-small cell lung cancer who have already received chemo-radiotherapy and are about to start immunotherapy with durvalumab. Researchers will look at how the immune system responds and whether that relates to survival. Th…